AIDS Alert Archives – March 1, 2008
March 1, 2008
View Issues
Full viral suppression newest trend seen in the "post-HAART" era
In what might be called the post-HAART era, there is an encouraging new trend of clinicians seeing greater numbers of patients who have undetectable viral loads, according to an HIV clinician who has been in the trenches for over two decades.Positive results involving HIV prevention for the mentally ill population
The HIV epidemic has disproportionately impacted people with mental illness and/or substance abuse problems, creating some inherent outreach and prevention targeting problems for providers and public health professionals.Late diagnosis/entry into HIV care can result in early deaths among infected
Despite public health initiatives pushing routine HIV testing, too many people infected with the virus are diagnosed later in the disease, leading to poor health outcomes, a study suggests.Status report on the female condom: What will increase use in the U.S.?
When you counsel on protection against HIV and other sexually transmitted diseases (STDs), where does the female condom fit into your message? While the female condom represents a woman-controlled form of protection against HIV and other STDs, its use has lagged in the United States since its introduction in 1993.FDA Notifications: FDA tentatively approves generic atazanavir
On Feb. 4, 2008, the FDA granted tentative approval for a generic formulation of atazanavir sulfate capsules, 100 mg, 150 mg, and 200 mg, manufactured by Emcure Pharmaceuticals of Pune, India. The application was reviewed under expedited review provisions for the President's Emergency Plan for AIDS Relief (PEPFAR).